Breast cancer treatments have evolved over the past decades, although several widely used
treatments have adverse cardiac effects. Radiotherapy generally improves the survival of …

Cardio-oncology is a subspecialty of cardiology. It was created to address oncology data
indicating that newly developed drugs for cancer treatment were having unanticipated …

Cardiotoxicity is a well-known complication following treatment with anthracyclines.
However, they are still widely used in chemotherapy for breast cancer, lymphoma, leukemia …

From detailed characterization of cardiac abnormalities to the assessment of cancer
treatment‐related cardiac dysfunction, cardiac MRI is playing a growing role in the …

Background Electrocardiography (ECG), predictive of adverse outcomes in the general
population, has not been studied in cancer survivors. We evaluated the prevalence of ECG …

Background Cardiac magnetic resonance imaging (MRI) is emerging as an important
diagnostic modality in the management of cardiovascular-related dysfunction in oncological …

Opinion statement Recent advances in cancer treatment and research have greatly
improved survival rates for patients with cancer. However, many of these cancer survivors …

Doxorubicin is a standard treatment option for breast cancer, lymphoma, and leukemia, but
its benefits are limited by its potential for cardiotoxicity. The primary objective of this study …

El desarrollo y uso de nuevos esquemas terapéuticos para el tratamiento del cáncer, solos
o asociados a esquemas conocidos (quimioterapia, radioterapia), pueden ocasionar …

Показано современное представление о кардиотоксичности химиотерапии у
пациентов с онкопатологией и главным образом хроническим лимфолейкозом …